scholarly journals An Equivalence between Wagering and Fair-Division Mechanisms

Author(s):  
Rupert Freeman ◽  
David M. Pennock ◽  
Jennifer Wortman Vaughan

We draw a surprising and direct mathematical equivalence between the class of allocation mechanisms for divisible goods studied in the context of fair division and the class of weakly budget-balanced wagering mechanisms designed for eliciting probabilities. The equivalence rests on the intuition that wagering is an allocation of financial securities among bettors, with a bettor’s value for each security proportional to her belief about the likelihood of a future event. The equivalence leads to theoretical advances and new practical approaches for both fair division and wagering. Known wagering mechanisms based on proper scoring rules yield fair allocation mechanisms with desirable properties, including the first strictly incentive compatible fair-division mechanism. At the same time, allocation mechanisms make for novel wagering rules, including one that requires only ordinal uncertainty judgments and one that outperforms existing rules in a range of simulations.

2017 ◽  
Vol 10 (2) ◽  
pp. 14-21 ◽  
Author(s):  
Arthur Carvalho

Incentive-compatible methods for eliciting beliefs, such as proper scoring rules, often rely on strong assumptions about how humans behave when making decisions under risk and uncertainty. For example, standard proper scoring rules assume that humans are risk neutral, an assumption that is often violated in practice. Under such an assumption, proper scoring rules induce honest reporting of beliefs, in a sense that experts maximize their expected scores from a proper scoring rule by honestly reporting their beliefs.Sandroni and Shmaya [Economic Theory Bulletin, volume 1, issue 1, 2013] suggested a remarkable mechanism based on proper scoring rules that induces honest reporting of beliefs without any assumptions on experts’ risk attitudes. In particular, the authors claimed that the mechanism relies only on the natural assumptions of probabilistic sophistication and dominance. We suggest in this paper that the reduction of compound lotteries axiom is another assumption required for Sandroni and Shmaya’s mechanism to induce honest reporting of beliefs. We further elaborate on the implications of such an extra assumption in light of recent findings regarding the reduction of compound lotteries axiom.


Author(s):  
Bruno de Finetti ◽  
Maria Carla Galavotti ◽  
Hykel Hosni ◽  
Alberto Mura

2018 ◽  
Vol 6 (3-4) ◽  
pp. 343-376 ◽  
Author(s):  
Arthur Carvalho ◽  
Stanko Dimitrov ◽  
Kate Larson

2015 ◽  
Vol 10 (2) ◽  
pp. 479-499 ◽  
Author(s):  
A. Philip Dawid ◽  
Monica Musio

2009 ◽  
Vol 76 (4) ◽  
pp. 1461-1489 ◽  
Author(s):  
THEO OFFERMAN ◽  
JOEP SONNEMANS ◽  
GIJS VAN DE KUILEN ◽  
PETER P. WAKKER

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 427-427 ◽  
Author(s):  
Ulrich Robert Mansmann ◽  
Ute Sartorius ◽  
Ruediger Paul Laubender ◽  
Clemens Albrecht Giessen ◽  
Regina Esser ◽  
...  

427 Background: The extent of tumor shrinkage in patients (pts) receiving chemotherapy +/- monoclonal antibodies has prognostic value for PFS and OS. "Deepness of response (DpR)" is a new efficacy outcome measure that could explain the impact of tumor shrinkage on long-term survival outcome. If shrinkage takes place DpR is the percentage of tumor shrinkage observed at the nadir compared to baseline. DpR is 0 for no change and negative if the tumor load increases. Longest diameter (LD) based on RECIST or a calculated tumor volume (ASCO GI 2012 #635) can quantify the tumor load at distinct time points. A joint model was presented (ASCO GI 2012 #580, ASCO 2012 #3603) which allows us to relate DpR to individual post-progression survival (PPS) time. Methods: Based on the data from 2 randomized trials (CRYSTAL, n=1198; OPUS, n=337), 4 treatment regimens (FOLFIRI +/- cetuximab and FOLFOX4 +/- cetuximab) were studied. A joint model was used to quantify individual changes in tumor size over time and to relate these changes to PFS and OS. Relationships between baseline tumor load and DpR and PPS were studied. Proper scoring rules were used to assess whether the LD-based or the volume-based approach allowed a better prediction of individual prognosis. Results: Results are reported for the CRYSTAL study using LD-based measures for 663 pts with KRAS wild-type tumors and imaging data. The 348 pts treated with FOLFIRI alone had a mean DpR of 35.52% (Interquartile range [IR]:12.09%, 59.86%), minimum DpR -80%. The 315 pts treated with FOLFIRI + cetuximab had a mean DpR of 50.07% (IR: 22.87%, 79.55%) and a minimum DpR of -49%. The DpR was significantly different between the 2 groups (p<0.00001). Individual DpR is a significant prognostic factor for PPS time in both the LD-based (p=0.0023) and volume-based (p=0.0003) models. Proper scoring rules provided evidence of a more precise estimation of individual PPS time based on volume algorithm-measured DpR. Results of the OPUS study will be presented. Conclusions: Our results emphasize the value of the variable DpR as a new efficacy outcome measure for clinical trials. The tumor-shrinking capacity of cetuximab was shown to be associated with its ability to prolong PPS.


Sign in / Sign up

Export Citation Format

Share Document